Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 1st 3Qtrs Business Results
February 9, 2004
- Antihistamic Drugs Marketing Stiffer Competition (2)
February 9, 2004
- Approval for Levitra, Sandostatin LAR Recommended
February 9, 2004
- BUSINESS NEWS IN BRIEF
February 9, 2004
- Website News
February 9, 2004
- BULLETIN
February 9, 2004
- Gov't-managed Health Insurance Reports 1st Surplus in 10 Yrs
February 9, 2004
- Cultural Sensitivity Is Very Important: Mr Mazzo of AMO
February 9, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 9, 2004
- M-VAC Therapy Approved
February 9, 2004
- Anunal Business Results
February 9, 2004
- Approval of 15 New Drugs Notified
February 9, 2004
- Semi-anunal Business Results
February 9, 2004
- 30 NCEs Approved in January-November 2003: PFSB
February 9, 2004
- 3rd Qtr Business Results
February 9, 2004
- 70%-Multiple Rule to Be Used in Initial NHI Listing for Generics
February 9, 2004
- PRESS SEMINAR
February 9, 2004
- 5 Deaths by Interstitial Pneumonia Linked to Aventis' Arava
February 9, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 9, 2004
- Nat'l Hospitals, Sanatoriums to Fully Pay Drug Costs: Health Minister
February 9, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…